What We're Reading: Page 42
Industry reads hand-picked by our editors
Jan 27, 2025
-
Bloomberg
Merck’s $8 Billion Cancer Vaccine Faces First US Jury Trial
-
The Wall Street Journal
Pfizer to Pay $60 Million in Kickback, False Claims Settlement
-
Financial Times
China investigates generic drugs over safety concerns
Jan 24, 2025
-
Semafor
Pfizer CEO Albert Bourla on Trump and the coming collapse of the status quo
-
The New York Times
ExThera Claimed Its Device Could Cure Cancer. But Patients Died.
-
Nature News
What went wrong at 23andMe? Why the genetic-data giant risks collapse
-
Reuters
WHO chief to cut costs, reset priorities after US exit, document shows
Jan 23, 2025
-
Science
Trump hits NIH with ‘devastating’ freezes on meetings, travel, communications, and hiring
-
Science
The new science of menopause: these emerging therapies could change women’s health
-
Endpoints News
Biogen makes cuts across its research unit, shifting focus to ‘external opportunities’
Jan 22, 2025
Jan 21, 2025
-
The Wall Street Journal
Beaten Down Under Biden, Big Pharma Hopes for New Chapter Under Trump
-
Bloomberg Law
Biogen Sued by Neuroscience Company Sage After Buyout Offer
-
Nature News
Trump’s science advisers: how they could influence his second presidency
Previous
